<p>啓迪醫療系統公司（NYSE:INSP - 獲取免費報告）週三股價創下 52 周新低，此前摩根大通將該股目標價從 67.00 美元下調至 54.00 美元。摩根大通目前對該股持中性評級。啓迪醫療系統的股價最低曾達到 44.41 美元，最後交易價為 48.2390 美元，成交量為 4487693 股。該股此前收盤價為 54.84 美元。</p>
<ul>
<li>艾利 Lilly 股票上漲：GLP-1 Zepbound 目標睡眠呼吸暫停市場</li>
</ul>
<p>其他一些股票分析師也對 INSP 發表了評論。Evercore 在週二的報告中將啓迪醫療系統的目標價設定為 55.00 美元。Truist Financial 將啓迪醫療系統的目標價從 64.00 美元下調至 50.00 美元，並在週二的報告中對該股給予 “持有” 評級。Robert W. Baird 將啓迪醫療系統的目標價從 63.00 美元下調至 50.00 美元，並在週二的報告中對該股給予 “中性” 評級。瑞銀集團在 2 月 13 日的報告中將啓迪醫療系統的目標價設定為 67.00 美元。最後，Stifel Nicolaus 在週二的報告中將啓迪醫療系統的目標價從 70.00 美元下調至 65.00 美元，並對該股給予 “買入” 評級。四位分析師對該股給予 “買入” 評級，十五位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股目前的平均評級為 “持有”，共識目標價為 85.00 美元。</p>
<p><strong>查看我們最新的 INSP 股票報告</strong></p>
<h2>啓迪醫療系統新聞摘要</h2>
<ul>
<li>啓迪醫療上漲 15% 後突破，分析師稱其為買入</li>
</ul>
<p>以下是本週影響啓迪醫療系統的主要新聞：</p>
<ul>
<li>積極情緒：第一季度超出預期——報告每股收益 0.10 美元（預期為-0.28 美元）和收入 2.046 億美元（預期約為 2 億美元），顯示基礎業務仍然盈利。第一季度新聞稿</li>
<li>積極情緒：一些經紀商保持建設性立場（Stifel 維持 “買入”，瑞穗維持 “跑贏大盤”），即使在下調目標後，如果指導風險緩解，仍有潛在上行空間。分析師反應（Benzinga）</li>
<li>中性情緒：美國銀行重申中性評級，目標價為 53 美元——這一適度謹慎的觀點反映了市場的觀望態度。美國銀行重申</li>
<li>消極情緒：管理層將 2026 財年的指導下調至每股收益 0.75-1.25 美元和收入 8.25 億-8.75 億美元，而共識預期為每股收益約 1.99 美元和收入約 9.61 億美元——大幅下調指導是主要的負面催化劑。2026 財年指導下調</li>
<li>消極情緒：公司提到報銷/編碼不確定性和 WISeR 項目帶來的干擾，導致手術量減少——這些運營阻力可能會對近期收入恢復施加壓力。報銷與 WISeR 問題</li>
<li>消極情緒：多家經紀商下調目標價（摩根大通 67→54 美元；富國銀行 70→56 美元；Truist 64→50 美元；Baird 63→50 美元），共識下調並增加了賣出壓力，儘管仍有一些買入/跑贏大盤評級。分析師目標價變動（摩根大通/TickerReport）</li>
</ul>
<h2>機構投資者對啓迪醫療系統的看法</h2>
<p>一些機構投資者最近調整了對該股的持有。Principal Financial Group Inc. 在第一季度將其在啓迪醫療系統的股份增加了 1.0%。Principal Financial Group Inc. 目前擁有 126,788 股該公司股票，價值 6,540,000 美元，此前在上個季度又購買了 1,269 股。Fifth Third Bancorp 在第一季度將其在啓迪醫療系統的股份增加了 1,794.4%。Fifth Third Bancorp 目前擁有 6,441 股該公司股票，價值 332,000 美元，此前在上個季度又購買了 6,101 股。紐約州教師退休系統在第一季度將其在啓迪醫療系統的股份增加了 9.3%。紐約州教師退休系統目前擁有 23,599 股該公司股票，價值 1,217,000 美元，此前在上個季度又購買了 2,004 股。Y Intercept Hong Kong Ltd 在第一季度將其在啓迪醫療系統的股份增加了 124.1%。Y Intercept Hong Kong Ltd 目前擁有 158,274 股該公司股票，價值 8,164,000 美元，此前在上個季度又購買了 87,639 股。最後，Leonteq Securities AG 在第一季度將其在啓迪醫療系統的股份增加了 187.3%。Leonteq Securities AG 目前擁有 22,812 股該公司股票，價值 1,177,000 美元，此前在上個季度又購買了 14,873 股。機構投資者和對沖基金持有該公司 94.91% 的股份。</p>
<h2>啓迪醫療系統股票表現</h2>
<ul>
<li>小型股是否預示市場下跌？</li>
</ul>
<p>該公司的市值為 13.9 億美元，市盈率為 10.74，市盈增長比率為 2.83，貝塔值為 0.83。該公司的 50 日移動平均價格為 56.51 美元，200 日移動平均價格為 79.43 美元。</p>
<p>啓迪醫療系統（NYSE:INSP - 獲取免費報告）最後一次發佈季度財報是在 5 月 4 日，報告每股收益為 0.10 美元，超出共識預期的-0.28 美元 0.38 美元。該季度的收入為 2.0458 億美元，而分析師預期為 2.0004 億美元。啓迪醫療系統的淨利潤率為 14.33%，股本回報率為 10.66%。啓迪醫療系統的季度收入同比增長 1.6%。在去年同期，該公司每股收益為 0.10 美元。啓迪醫療系統已將其 2026 財年的指導設定為 0.750-1.250 美元每股收益。分析師平均預測啓迪醫療系統將在當前財年發佈 1.82 美元每股收益。</p>
<h2>關於啓迪醫療系統</h2>
<p>（獲取免費報告）</p>
<p>啓迪醫療系統公司是一家醫療科技公司，專注於用於治療阻塞性睡眠呼吸暫停（OSA）的可植入神經刺激設備。該公司的旗艦產品 Inspire® 系統，通過對舌下神經的定向刺激，在睡眠期間保持氣道通暢，為對持續正壓呼吸機（CPAP）設備不耐受或管理不當的患者提供了一種替代療法。</p>
<p>Inspire 系統由一個可植入的脈衝發生器、一個監測呼吸模式的傳感導線和一個激活舌下神經的刺激導線組成。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們認為比啓迪醫療系統更好的股票</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在啓迪醫療系統嗎？</h2>
<p>在考慮啓迪醫療系統之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前立即購買的股票……而啓迪醫療系統並不在名單上。</p>
<p>儘管啓迪醫療系統目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

啟迪醫療

標普健康醫療設備 ETF - SPDR

美國醫藥設備 ETF - iShares

<p>啓迪醫療系統（NYSE:INSP）在摩根大通將其目標股價從 67 美元下調至 54 美元后，創下了新的 12 個月低點。該股最低交易價為 44.41 美元，收盤價為 48.24 美元，交易量為 4,487,693 股。分析師的評級各不相同，四位分析師推薦買入，十五位分析師建議持有。公司還大幅下調了 2026 財年的指引，原因是報銷問題和運營挑戰。機構投資者持有該股 94.91%，儘管近期評級下調，但仍反映出強烈的投資興趣</p>

<p>Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report)'s share price hit a new 52-week low on Wednesday after JPMorgan Chase &amp; Co. lowered their price target on the stock from $67.00 to $54.00. JPMorgan Chase &amp; Co. currently has a neutral rating on the stock. Inspire Medical Systems traded as low as $44.41 and last traded at $48.2390, with a volume of 4487693 shares. The stock had previously closed at $54.84.</p>
<div class="lb-trans"><p>啓迪醫療系統公司（NYSE:INSP - 獲取免費報告）週三股價創下 52 周新低，此前摩根大通將該股目標價從 67.00 美元下調至 54.00 美元。摩根大通目前對該股持中性評級。啓迪醫療系統的股價最低曾達到 44.41 美元，最後交易價為 48.2390 美元，成交量為 4487693 股。該股此前收盤價為 54.84 美元。</p>
</div><ul>
<li>Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market</li>
</ul>
<div class="lb-trans"><ul>
<li>艾利 Lilly 股票上漲：GLP-1 Zepbound 目標睡眠呼吸暫停市場</li>
</ul>
</div><p>A number of other equities analysts have also commented on INSP. Evercore set a $55.00 price objective on shares of Inspire Medical Systems in a report on Tuesday. Truist Financial cut their price objective on shares of Inspire Medical Systems from $64.00 to $50.00 and set a &#34;hold&#34; rating on the stock in a report on Tuesday. Robert W. Baird cut their price objective on shares of Inspire Medical Systems from $63.00 to $50.00 and set a &#34;neutral&#34; rating on the stock in a report on Tuesday. UBS Group set a $67.00 price objective on shares of Inspire Medical Systems in a report on Friday, February 13th. Finally, Stifel Nicolaus cut their price objective on shares of Inspire Medical Systems from $70.00 to $65.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday. Four analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Hold&#34; and a consensus price target of $85.00.</p>
<div class="lb-trans"><p>其他一些股票分析師也對 INSP 發表了評論。Evercore 在週二的報告中將啓迪醫療系統的目標價設定為 55.00 美元。Truist Financial 將啓迪醫療系統的目標價從 64.00 美元下調至 50.00 美元，並在週二的報告中對該股給予 “持有” 評級。Robert W. Baird 將啓迪醫療系統的目標價從 63.00 美元下調至 50.00 美元，並在週二的報告中對該股給予 “中性” 評級。瑞銀集團在 2 月 13 日的報告中將啓迪醫療系統的目標價設定為 67.00 美元。最後，Stifel Nicolaus 在週二的報告中將啓迪醫療系統的目標價從 70.00 美元下調至 65.00 美元，並對該股給予 “買入” 評級。四位分析師對該股給予 “買入” 評級，十五位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股目前的平均評級為 “持有”，共識目標價為 85.00 美元。</p>
</div><p><strong>View Our Latest Stock Report on INSP</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 INSP 股票報告</strong></p>
</div><h2>Inspire Medical Systems News Summary</h2>
<div class="lb-trans"><h2>啓迪醫療系統新聞摘要</h2>
</div><ul>
<li>Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>啓迪醫療上漲 15% 後突破，分析師稱其為買入</li>
</ul>
</div><p>Here are the key news stories impacting Inspire Medical Systems this week:</p>
<div class="lb-trans"><p>以下是本週影響啓迪醫療系統的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Q1 beat consensus — reported $0.10 EPS (vs. est. -$0.28) and $204.6M revenue (vs. est. ~$200M), showing the underlying business still generates profitability. Q1 Press Release</li>
<li>Positive Sentiment: Some brokers kept constructive stances (Stifel maintained a &#34;buy&#34; and Mizuho an &#34;outperform&#34;) even after lowering targets, which provides potential upside if guidance risks ease. Analyst Reactions (Benzinga)</li>
<li>Neutral Sentiment: Bank of America reaffirmed a neutral rating with a $53 target — a modestly cautious view that mirrors the market’s wait‑and‑see stance. BofA Reaffirmation</li>
<li>Negative Sentiment: Management cut FY‑2026 guidance to $0.75–$1.25 EPS and $825M–$875M revenue vs. consensus ~ $1.99 EPS and ~$961M revenue — the sizable guidance cut is the primary negative catalyst. FY‑2026 Guidance Cut</li>
<li>Negative Sentiment: Company cited reimbursement/coding uncertainty and disruptions from the WISeR program that have reduced procedure volumes — operational headwinds that could pressure near‑term revenue recovery. Reimbursement &amp; WISeR Issues</li>
<li>Negative Sentiment: Multiple brokers cut price targets (JPMorgan $67→$54; Wells Fargo $70→$56; Truist $64→$50; Baird $63→$50), shifting consensus lower and adding selling pressure despite some remaining buy/outperform ratings. Analyst PT Moves (JPMorgan/TickerReport)</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：第一季度超出預期——報告每股收益 0.10 美元（預期為-0.28 美元）和收入 2.046 億美元（預期約為 2 億美元），顯示基礎業務仍然盈利。第一季度新聞稿</li>
<li>積極情緒：一些經紀商保持建設性立場（Stifel 維持 “買入”，瑞穗維持 “跑贏大盤”），即使在下調目標後，如果指導風險緩解，仍有潛在上行空間。分析師反應（Benzinga）</li>
<li>中性情緒：美國銀行重申中性評級，目標價為 53 美元——這一適度謹慎的觀點反映了市場的觀望態度。美國銀行重申</li>
<li>消極情緒：管理層將 2026 財年的指導下調至每股收益 0.75-1.25 美元和收入 8.25 億-8.75 億美元，而共識預期為每股收益約 1.99 美元和收入約 9.61 億美元——大幅下調指導是主要的負面催化劑。2026 財年指導下調</li>
<li>消極情緒：公司提到報銷/編碼不確定性和 WISeR 項目帶來的干擾，導致手術量減少——這些運營阻力可能會對近期收入恢復施加壓力。報銷與 WISeR 問題</li>
<li>消極情緒：多家經紀商下調目標價（摩根大通 67→54 美元；富國銀行 70→56 美元；Truist 64→50 美元；Baird 63→50 美元），共識下調並增加了賣出壓力，儘管仍有一些買入/跑贏大盤評級。分析師目標價變動（摩根大通/TickerReport）</li>
</ul>
</div><h2>Institutional Investors Weigh In On Inspire Medical Systems</h2>
<div class="lb-trans"><h2>機構投資者對啓迪醫療系統的看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. raised its stake in shares of Inspire Medical Systems by 1.0% in the 1st quarter. Principal Financial Group Inc. now owns 126,788 shares of the company's stock valued at $6,540,000 after purchasing an additional 1,269 shares in the last quarter. Fifth Third Bancorp raised its stake in shares of Inspire Medical Systems by 1,794.4% in the 1st quarter. Fifth Third Bancorp now owns 6,441 shares of the company's stock valued at $332,000 after purchasing an additional 6,101 shares in the last quarter. New York State Teachers Retirement System raised its stake in shares of Inspire Medical Systems by 9.3% in the 1st quarter. New York State Teachers Retirement System now owns 23,599 shares of the company's stock valued at $1,217,000 after purchasing an additional 2,004 shares in the last quarter. Y Intercept Hong Kong Ltd raised its stake in shares of Inspire Medical Systems by 124.1% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 158,274 shares of the company's stock valued at $8,164,000 after purchasing an additional 87,639 shares in the last quarter. Finally, Leonteq Securities AG raised its stake in shares of Inspire Medical Systems by 187.3% in the 1st quarter. Leonteq Securities AG now owns 22,812 shares of the company's stock valued at $1,177,000 after purchasing an additional 14,873 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者最近調整了對該股的持有。Principal Financial Group Inc. 在第一季度將其在啓迪醫療系統的股份增加了 1.0%。Principal Financial Group Inc. 目前擁有 126,788 股該公司股票，價值 6,540,000 美元，此前在上個季度又購買了 1,269 股。Fifth Third Bancorp 在第一季度將其在啓迪醫療系統的股份增加了 1,794.4%。Fifth Third Bancorp 目前擁有 6,441 股該公司股票，價值 332,000 美元，此前在上個季度又購買了 6,101 股。紐約州教師退休系統在第一季度將其在啓迪醫療系統的股份增加了 9.3%。紐約州教師退休系統目前擁有 23,599 股該公司股票，價值 1,217,000 美元，此前在上個季度又購買了 2,004 股。Y Intercept Hong Kong Ltd 在第一季度將其在啓迪醫療系統的股份增加了 124.1%。Y Intercept Hong Kong Ltd 目前擁有 158,274 股該公司股票，價值 8,164,000 美元，此前在上個季度又購買了 87,639 股。最後，Leonteq Securities AG 在第一季度將其在啓迪醫療系統的股份增加了 187.3%。Leonteq Securities AG 目前擁有 22,812 股該公司股票，價值 1,177,000 美元，此前在上個季度又購買了 14,873 股。機構投資者和對沖基金持有該公司 94.91% 的股份。</p>
</div><h2>Inspire Medical Systems Stock Performance</h2>
<div class="lb-trans"><h2>啓迪醫療系統股票表現</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否預示市場下跌？</li>
</ul>
</div><p>The firm has a market cap of $1.39 billion, a price-to-earnings ratio of 10.74, a price-to-earnings-growth ratio of 2.83 and a beta of 0.83. The business's 50 day moving average price is $56.51 and its 200-day moving average price is $79.43.</p>
<div class="lb-trans"><p>該公司的市值為 13.9 億美元，市盈率為 10.74，市盈增長比率為 2.83，貝塔值為 0.83。該公司的 50 日移動平均價格為 56.51 美元，200 日移動平均價格為 79.43 美元。</p>
</div><p>Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.38. The firm had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.66%. Inspire Medical Systems's quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, analysts forecast that Inspire Medical Systems, Inc. will post 1.82 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>啓迪醫療系統（NYSE:INSP - 獲取免費報告）最後一次發佈季度財報是在 5 月 4 日，報告每股收益為 0.10 美元，超出共識預期的-0.28 美元 0.38 美元。該季度的收入為 2.0458 億美元，而分析師預期為 2.0004 億美元。啓迪醫療系統的淨利潤率為 14.33%，股本回報率為 10.66%。啓迪醫療系統的季度收入同比增長 1.6%。在去年同期，該公司每股收益為 0.10 美元。啓迪醫療系統已將其 2026 財年的指導設定為 0.750-1.250 美元每股收益。分析師平均預測啓迪醫療系統將在當前財年發佈 1.82 美元每股收益。</p>
</div><h2>About Inspire Medical Systems</h2>
<div class="lb-trans"><h2>關於啓迪醫療系統</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.</p>
<div class="lb-trans"><p>啓迪醫療系統公司是一家醫療科技公司，專注於用於治療阻塞性睡眠呼吸暫停（OSA）的可植入神經刺激設備。該公司的旗艦產品 Inspire® 系統，通過對舌下神經的定向刺激，在睡眠期間保持氣道通暢，為對持續正壓呼吸機（CPAP）設備不耐受或管理不當的患者提供了一種替代療法。</p>
</div><p>The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.</p>
<div class="lb-trans"><p>Inspire 系統由一個可植入的脈衝發生器、一個監測呼吸模式的傳感導線和一個激活舌下神經的刺激導線組成。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Inspire Medical Systems</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比啓迪醫療系統更好的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Inspire Medical Systems Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在啓迪醫療系統嗎？</h2>
</div><p>Before you consider Inspire Medical Systems, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮啓迪醫療系統之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前立即購買的股票……而啓迪醫療系統並不在名單上。</p>
</div><p>While Inspire Medical Systems currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管啓迪醫療系統目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Inspire Medical Systems (NYSE:INSP) Reaches New 12-Month Low on Analyst Downgrade

Market Beat

摩根大通

禮來

Evercore

Truist Financial

瑞銀集團

Stifel Financial

瑞穗金融集團

Mizuho Financial Group, Inc.

美國銀行

富國銀行

信安金融

五三銀行

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

五三銀行-存託優先股Series K

Fifth Third Bancorp Pref Shares FITBM 6.875 Perp 10/01/30

五三銀行-Series A

啓迪醫療系統（NYSE:INSP）因分析師下調評級而創下 12 個月新低